Wiek van Gilst

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Living Beings

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Wong Liza S M; van der Harst Pim; de Boer Rudolf A; Codd Veryan; Huzen Jardi; Samani Nilesh J; Hillege Hans L; Voors Adriaan A; van Gilst Wiek H; Jaarsma Tiny; van Veldhuisen Dirk J
Renal dysfunction is associated with shorter telomere length in heart failure.
de Boer Rudolf A; Voors Adriaan A; Muntendam Pieter; van Gilst Wiek H; van Veldhuisen Dirk J
Galectin-3: a novel mediator of heart failure development and progression.
Meijering Bernadet D M; Juffermans Lynda J M; van Wamel Annemieke; Henning Rob H; Zuhorn Inge S; Emmer Marcia; Versteilen Amanda M G; Paulus Walter J; van Gilst Wiek H; Kooiman Klazina; de Jong Nico; Musters René J P; Deelman Leo E; Kamp Otto
Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Wiek van Gilst (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Wong Liza S M; van der Harst Pim; de Boer Rudolf A; Codd Veryan; Huzen Jardi; Samani Nilesh J; Hillege Hans L; Voors Adriaan A; van Gilst Wiek H; Jaarsma Tiny; van Veldhuisen Dirk J
Renal dysfunction is associated with shorter telomere length in heart failure.
Clinical research in cardiology : official journal of the German Cardiac Society 2009;98(10):629-34.
2009: de Boer Rudolf A; Voors Adriaan A; Muntendam Pieter; van Gilst Wiek H; van Veldhuisen Dirk J
Galectin-3: a novel mediator of heart failure development and progression.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2009;11(9):811-7.
2009: Meijering Bernadet D M; Juffermans Lynda J M; van Wamel Annemieke; Henning Rob H; Zuhorn Inge S; Emmer Marcia; Versteilen Amanda M G; Paulus Walter J; van Gilst Wiek H; Kooiman Klazina; de Jong Nico; Musters René J P; Deelman Leo E; Kamp Otto
Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation.
Circulation research 2009;104(5):679-87.
2009: Xu Ying; Henning Rob H; Sandovici Maria; van der Want Johannes J; van Gilst Wiek H; Buikema Hendrik
Enhanced myogenic constriction of mesenteric artery in heart failure relates to decreased smooth muscle cell caveolae numbers and altered AT1- and epidermal growth factor-receptor function.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2009;11(3):246-55.
2009: Qian Cheng; Schoemaker Regien G; van Gilst Wiek H; Roks Anton J M
The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
Clinical science (London, England : 1979) 2009;116(4):301-14.
2009: Oeseburg Hisko; Iusuf Dilek; van der Harst Pim; van Gilst Wiek H; Henning Robert H; Roks Anton J M
Bradykinin protects against oxidative stress-induced endothelial cell senescence.
Hypertension 2009;53(2):417-22.
2009: Wong Liza S M; Oeseburg Hisko; de Boer Rudolf A; van Gilst Wiek H; van Veldhuisen Dirk J; van der Harst Pim
Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing.
Cardiovascular research 2009;81(2):244-52.
2009: Westendorp Bart; Hamming Inge; Szymanski Mariusz K; Navis Gerjan; van Goor Harry; Buikema Hendrik; van Gilst Wiek H; Schoemaker Regien G
Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor.
European journal of pharmacology 2009;602(2-3):373-9.
2009: Ulu Nadir; Schoemaker Regien G; Henning Robert H; Buikema Hendrik; Teerlink Tom; Zijlstra Freek J; Bakker Stephan J L; van Gilst Wiek H; Navis Gerjan
Proteinuria-associated endothelial dysfunction is strain dependent.
American journal of nephrology 2009;30(3):209-17.
2008: Qian C; Schoemaker R G; van Gilst W H; Yu B; Roks A J M
Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 2: Pharmacological targets, agents and intervention perspectives.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2008;16(10):337-43.
2008: Qian C; Schoemaker R G; van Gilst W H; Yu B; Roks A J M
Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 1: Cardiovascular progenitor cells, their functions and sources.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2008;16(9):305-9.
2008: Langeveld B E; Henning R H; de Smet B J G L; Zijlstra F; Driessen A; Tijsma E; van Gilst W H; Roks A
Rescue of arterial function by angiotensin-(1-7): towards improvement of endothelial function by drug-eluting stents.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2008;16(9):291-2.
2008: Jaarsma T; van der Wal M H L; Lesman-Leegte I; Luttik M L; Hogenhuis J; Veeger N J; Sanderman R; Hoes A W; van Gilst W H; Lok D J A; Dunselman P H J M; Tijssen J G P; Hillege H L; van Veldhuisen D J
[Value of basic and intensive management of patients with heart failure; results of a randomised controlled clinical trial]
Nederlands tijdschrift voor geneeskunde 2008;152(37):2016-21.
2008: Westenbrink B Daan; Oeseburg Hisko; Kleijn Lennaert; van der Harst Pim; Belonje Anne M S; Voors Adriaan A; Schoemaker Regien G; de Boer Rudolf A; van Veldhuisen Dirk J; van Gilst Wiek H
Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2008;22(4):265-74.
2008: van der Harst Pim; Asselbergs Folkert W; Hillege Hans L; Voors Adriaan A; van Veldhuisen Dirk J; van Gilst Wiek H;
Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria.
The American journal of cardiology 2008;102(2):223-5.
2008: van der Harst Pim; Wong Liza S M; de Boer Rudolf A; Brouilette Scott W; van der Steege Gerrit; Voors Adriaan A; Hall Alistair S; Samani Nilesh J; Wikstrand John; van Gilst Wiek H; van Veldhuisen Dirk J;
Possible association between telomere length and renal dysfunction in patients with chronic heart failure.
The American journal of cardiology 2008;102(2):207-10.
2008: van der Meer Peter; Lok Dirk J; Januzzi James L; de la Porte Pieta W Bruggink-Andre; Lipsic Erik; van Wijngaarden Jan; Voors Adriaan A; van Gilst Wiek H; van Veldhuisen Dirk J
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients.
European heart journal 2008;29(12):1510-5.
2008: Kuipers Irma; van der Harst Pim; Navis Gerjan; van Genne Linda; Morello Fulvio; van Gilst Wiek H; van Veldhuisen Dirk J; de Boer Rudolf A
Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system.
Hypertension 2008;51(6):1442-8.
2008: Ulu Nadir; Buikema Hendrik; van Gilst Wiek H; Navis Gerjan
Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2008;23(6):1854-60.
2008: Huzen J; van Veldhuisen D J; van Gilst W H; van der Harst P
[Telomeres and biological ageing in cardiovascular disease]
Nederlands tijdschrift voor geneeskunde 2008;152(22):1265-70.
2008: Belonje Anne M; Voors Adriaan A; van Gilst Wiek H; Anker Stefan D; Slart Riemer H; Tio Rene A; Zijlstra Felix; van Veldhuisen Dirk J;
Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III).
American heart journal 2008;155(5):817-22.
2008: Xu Ying; Buikema Hendrik; van Gilst Wiek H; Henning Rob H
Caveolae and endothelial dysfunction: filling the caves in cardiovascular disease.
European journal of pharmacology 2008;585(2-3):256-60.
2008: Iusuf Dilek; Henning Robert H; van Gilst Wiek H; Roks Anton J M
Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives.
European journal of pharmacology 2008;585(2-3):303-12.
2008: Ruifrok Willem-Peter T; de Boer Rudolf A; Westenbrink B Daan; van Veldhuisen Dirk J; van Gilst Wiek H
Erythropoietin in cardiac disease: new features of an old drug.
European journal of pharmacology 2008;585(2-3):270-7.
2008: Groenewegen Hendrik C; van der Harst Pim; Roks Anton J M; Buikema Hendrik; Zijlstra Felix; van Gilst Wiek H; de Smet Bart J G L
Effects of angiotensin II and angiotensin II type 1 receptor blockade on neointimal formation after stent implantation.
International journal of cardiology 2008;126(2):209-15.
2008: Westenbrink B Daan; de Boer Rudolf A; Voors Adriaan A; van Gilst Wiek H; van Veldhuisen Dirk J
Anemia in chronic heart failure: etiology and treatment options.
Current opinion in cardiology 2008;23(2):141-7.
2008: Chocron Sidney; Baillot Richard; Rouleau Jean Lucien; Warnica Wayne J; Block Pierre; Johnstone David; Myers Martin G; Calciu Cristina Dana; Nozza Anna; Martineau Pierre; van Gilst Wiek H;
Impact of previous percutaneous transluminal coronary angioplasty and/or stenting revascularization on outcomes after surgical revascularization: insights from the imagine study.
European heart journal 2008;29(5):673-9.
2008: van der Harst Pim; Böhm Michael; van Gilst Wiek H; van Veldhuisen Dirk J
The case for statin therapy in chronic heart failure.
Clinical research in cardiology : official journal of the German Cardiac Society 2008;97(3):139-46.
2008: van der Harst Pim; Groenewegen Hendrik C; Roks Anton J M; Buikema Hendrik; Zijlstra Felix; van Gilst Wiek H; de Smet Bart J G L
Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat.
Coronary artery disease 2008;19(1):47-53.
2008: Jaarsma Tiny; van der Wal Martje H L; Lesman-Leegte Ivonne; Luttik Marie-Louise; Hogenhuis Jochem; Veeger Nic J; Sanderman Robbert; Hoes Arno W; van Gilst Wiek H; Lok Dirk J A; Dunselman Peter H J M; Tijssen Jan G P; Hillege Hans L; van Veldhuisen Dirk J;
Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH).
Archives of internal medicine 2008;168(3):316-24.
2008: Lipsic Erik; Westenbrink B Daan; van der Meer Peter; van der Harst Pim; Voors Adriaan A; van Veldhuisen Dirk J; Schoemaker Regien G; van Gilst Wiek H
Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2008;10(1):22-9.
2008: Rouleau Jean L; Warnica Wayne J; Baillot Richard; Block Pierre J; Chocron Sidney; Johnstone David; Myers Martin G; Calciu Cristina-Dana; Dalle-Ave Sonia; Martineau Pierre; Mormont Christine; van Gilst Wiek H;
Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
Circulation 2008;117(1):24-31.
2008: Geluk Christiane A; Post Wendy J; Hillege Hans L; Tio René A; Tijssen Jan G P; van Dijk René B; Dijk W Arnold; Bakker Stephan J L; de Jong Paul E; van Gilst Wiek H; Zijlstra Felix
C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort.
Atherosclerosis 2008;196(1):372-82.
2008: Asselbergs Folkert W; van der Harst Pim; van Roon Arie M; Hillege Hans L; de Jong Paul E; Gans Reinold O B; Smit Andries J; van Gilst Wiek H
Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects.
Atherosclerosis 2008;196(1):349-55.
2008: van der Meer Peter; Lipsic Erik; van Gilst Wiek H; van Veldhuisen Dirk J
Anemia and erythropoietin in heart failure.
Heart failure monitor 2008;6(1):28-33.
2008: Groenewegen Hendrik C; Onuta Geanina; Goris Maaike; Zandvoort André; Zijlstra Felix; van Gilst Wiek H; Rozing Jan; de Smet Bart J G L; Roks Anton J M; Hillebrands Jan-Luuk
Non-bone marrow origin of neointimal smooth muscle cells in experimental in-stent restenosis in rats.
Journal of vascular research 2008;45(6):493-502.
2008: Asselbergs F W; van den Berg M P; Bakker S J; Signorovitch J E; Hillege H L; van Gilst W H; van Veldhuisen D J
N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2008;16(3):73-8.
2007: van de Wal Ruud M A; van der Harst Pim; Gerritsen Wim B M; van der Horst Fal; Plokker Thijs H W; Gansevoort Ron T; van Gilst Wiek H; Voors Adriaan A
Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2007;8(4):177-80.
2007: Meijering Bernadet D M; Henning Robert H; Van Gilst Wiek H; Gavrilovic Ivana; Van Wamel Annemieke; Deelman Leo E
Optimization of ultrasound and microbubbles targeted gene delivery to cultured primary endothelial cells.
Journal of drug targeting 2007;15(10):664-71.
2007: van der Harst Pim; Asselbergs Folkert W; Hillege Hans L; Bakker Stephan J L; Voors Adriaan A; van Veldhuisen Dirk J; van Gilst Wiek H;
Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
The American journal of cardiology 2007;100(10):1548-51.
2007: Oeseburg Hisko; Westenbrink B Daan; de Boer Rudolf A; van Gilst Wiek H; van Veldhuisen Dirk J; van der Harst Pim
Can critically short telomeres cause functional exhaustion of progenitor cells in postinfarction heart failure?
Journal of the American College of Cardiology 2007;50(19):1911-2; author reply 1912-3.
2007: Asselbergs Folkert W; Williams Scott M; Hebert Patricia R; Coffey Christopher S; Hillege Hans L; Snieder Harold; Navis Gerjan; Vaughan Douglas E; van Gilst Wiek H; Moore Jason H
The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context.
Human genetics 2007;122(3-4):275-81.
2007: van de Wal R M A; van der Harst P; Wagenaar L J; Wassmann S; Morshuis W J; Nickenig G; Buikema H; Plokker H W M; van Veldhuisen D J; van Gilst W H; Voors A A
Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease.
Journal of cardiovascular pharmacology 2007;50(4):372-9.
2007: Smilde Tom D J; Zuurman Mike W; Hillege Hans L; van Veldhuisen Dirk J; van Gilst Wiek H; van der Steege Gerrit; Voors Adriaan A; Kors Jan A; de Jong Paul E; Navis Gerjan
Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy.
American journal of hypertension 2007;20(10):1097-103.
2007: Belonje Anne M S; Voors Adriaan A; van Gilst Wiek H; van Veldhuisen Dirk J
Erythropoietin in chronic heart failure.
Congestive heart failure (Greenwich, Conn.) 2007;13(5):289-92.
2007: Westenbrink B Daan; Voors Adriaan A; Ruifrok Willem-Peter T; van Gilst Wiek H; van Veldhuisen Dirk J
Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond.
Current heart failure reports 2007;4(3):127-33.
2007: Westenbrink B Daan; Lipsic Erik; van der Meer Peter; van der Harst Pim; Oeseburg Hisko; Du Marchie Sarvaas Gideon J; Koster Johan; Voors Adriaan A; van Veldhuisen Dirk J; van Gilst Wiek H; Schoemaker Regien G
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.
European heart journal 2007;28(16):2018-27.
2007: van der Wal Martje H L; Jaarsma Tiny; Moser Debra K; van Gilst Wiek H; van Veldhuisen Dirk J
Unraveling the mechanisms for heart failure patients' beliefs about compliance.
Heart & lung : the journal of critical care 2007;36(4):253-61.
2007: Asselbergs Folkert W; van Gilst Wiek H
Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
Current opinion in cardiology 2007;22(4):267-72.
2007: Qian Cheng; Tio René A; Roks Anton J M; Boddeus Kristien M; Harmsen Martin C; van Gilst Wiek H; Schoemaker Regien G
A promising technique for transplantation of bone marrow-derived endothelial progenitor cells into rat heart.
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2007;16(3):127-35.
2007: van der Harst Pim; van der Steege Gerrit; de Boer Rudolf A; Voors Adriaan A; Hall Alistair S; Mulder Marcel J; van Gilst Wiek H; van Veldhuisen Dirk J;
Telomere length of circulating leukocytes is decreased in patients with chronic heart failure.
Journal of the American College of Cardiology 2007;49(13):1459-64.
2007: Xu Y; Henning R H; van der Want J J L; van Buiten A; van Gilst W H; Buikema H
Disruption of endothelial caveolae is associated with impairment of both NO- as well as EDHF in acetylcholine-induced relaxation depending on their relative contribution in different vascular beds.
Life sciences 2007;80(18):1678-85.
2007: Asselbergs Folkert W; Williams Scott M; Hebert Patricia R; Coffey Christopher S; Hillege Hans L; Navis Gerjan; Vaughan Douglas E; van Gilst Wiek H; Moore Jason H
Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.
Genomics 2007;89(3):362-9.
2007: Asselbergs F W; Williams S M; Hebert P R; Coffey C S; Hillege H L; Navis G; Vaughan D E; van Gilst W H; Moore J H
Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits.
Journal of thrombosis and haemostasis : JTH 2007;5(2):313-20.
2007: Xu Y; Henning R H; Lipsic E; van Buiten A; van Gilst W H; Buikema H
Acetylcholine stimulated dilatation and stretch induced myogenic constriction in mesenteric artery of rats with chronic heart failure.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2007;9(2):144-51.
2007: Westenbrink B Daan; Visser Folkert W; Voors Adriaan A; Smilde Tom D J; Lipsic Erik; Navis Gerjan; Hillege Hans L; van Gilst Wiek H; van Veldhuisen Dirk J
Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well.
European heart journal 2007;28(2):166-71.
2007: Sturm H B; van Gilst W H; Veeger N; Haaijer-Ruskamp F M
Prescribing for chronic heart failure in Europe: does the country make the difference? A European survey.
Pharmacoepidemiology and drug safety 2007;16(1):96-103.
2007: Loot A E; Roks A J M; Westermann D; Orzechowski H-D; Tschöpe C; Wilschut J C; Tio R A; van Gilst W H; Henning R H
Cardiac overexpression of human VEGF(165) by recombinant Semliki Forest virus leads to adverse effects in pressure-induced heart failure.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2007;15(10):335-41.
2007: Geluk Christiane A; Dikkers Riksta; Kors Jan A; Tio René A; Slart Riemer H J A; Vliegenthart Rozemarijn; Hillege Hans L; Willems Tineke P; de Jong Paul E; van Gilst Wiek H; Oudkerk Matthijs; Zijlstra Felix
Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study.
BMC cardiovascular disorders 2007;7():19.
2007: Geluk C A; Tio R A; Tijssen J G P; van Dijk R B; Dijk W A; Hillege H L; de Jong P E; van Gilst W H; Zijlstra F
Clinical characteristics, cardiac events and coronary angiographic findings in the prospective PREVEND cohort: an observational study.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2007;15(4):133-41.
2006: Lipsic Erik; Schoemaker Regien G; van der Meer Peter; Voors Adriaan A; van Veldhuisen Dirk J; van Gilst Wiek H
Protective effects of erythropoietin in cardiac ischemia: from bench to bedside.
Journal of the American College of Cardiology 2006;48(11):2161-7.
2006: van de Wal Ruud M A; Gansevoort Ron T; van der Harst Pim; Boomsma Frans; Thijs Plokker H W; van Veldhuisen Dirk J; de Jong Paul E; van Gilst Wiek H; Voors Adriaan A
Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients.
Hypertension 2006;48(5):870-6.
2006: Atthobari Jarir; Brantsma Auke H; Gansevoort Ron T; Visser Sipke T; Asselbergs Folkert W; van Gilst Wiek H; de Jong Paul E; de Jong-van den Berg Lolkje T W;
The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(11):3106-14.
2006: Asselbergs Folkert W; Williams Scott M; Hebert Patricia R; Coffey Christopher S; Hillege Hans L; Navis Gerjan; Vaughan Douglas E; van Gilst Wiek H; Moore Jason H
The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
Thrombosis and haemostasis 2006;96(4):471-7.
2006: van der Harst Pim; Asselbergs Folkert W; Buikema Hendrik; Voors Adriaan A; van Veldhuisen Dirk J; van Gilst Wiek H
Effects of C-reactive protein and cholesterol on responsiveness in vitro of the internal thoracic artery to angiotensin II in patients having coronary artery bypass grafting.
The American journal of cardiology 2006;98(6):751-3.
2006: van der Harst Pim; Voors Adriaan A; van Gilst Wiek H; Böhm Michael; van Veldhuisen Dirk J
Statins in the treatment of chronic heart failure: a systematic review.
PLoS medicine 2006;3(8):e333.
2006: van der Harst Pim; Voors Adriaan A; van Gilst Wiek H; Böhm Michael; van Veldhuisen Dirk J
Statins in the treatment of chronic heart failure: biological and clinical considerations.
Cardiovascular research 2006;71(3):443-54.
2006: van Gilst Wiek H; Warnica J Wayne; Baillot Richard; Johnstone David; Calciu Cristina-Dana; Block Pierre; Myers Martin G; Chocron Sidney; Rouleau Jean-Lucien;
Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.
American heart journal 2006;151(6):1240-6.
2006: van der Harst Pim; Voors Adriaan A; Volbeda Meint; Buikema Hendrik; van Veldhuisen Dirk J; van Gilst Wiek H
Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting.
The American journal of cardiology 2006;97(12):1697-701.
2006: Lipsic Erik; van der Meer Peter; Voors Adriaan A; Westenbrink B Daan; van den Heuvel Ad F M; de Boer Hetty C; van Zonneveld Anton J; Schoemaker Regien G; van Gilst Wiek H; Zijlstra Felix; van Veldhuisen Dirk J
A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2006;20(2):135-41.
2006: Atthobari Jarir; Asselbergs Folkert W; Boersma Cornelis; de Vries Robin; Hillege Hans L; van Gilst Wiek H; Gansevoort Ron T; de Jong Paul E; de Jong-van den Berg Lolkje T W; Postma Maarten J;
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Clinical therapeutics 2006;28(3):432-44.
2006: Asselbergs Folkert W; van der Harst P; van Gilst Wiek H
Letter regarding article by Arnlov et al, "low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals".
Circulation 2006;113(10):e406; author reply e406-7.
2006: Westendorp Bart; Schoemaker Regien G; Buikema Hendrik; Boomsma Frans; van Veldhuisen Dirk J; van Gilst Wiek H
Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2006;8(2):122-30.
2006: Voors Adriaan A; van Veldhuisen Dirk J; van Gilst Wiek H
The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2006;20(1):69-73.
2006: van der Harst Pim; Smilde Tom D J; Buikema Hendrik; Voors Adriaan A; Navis Gerjan; van Veldhuisen Dirk J; van Gilst Wiek H
Vascular function and mild renal impairment in stable coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(2):379-84.
2006: van der Wal Martje H L; Jaarsma Tiny; Moser Debra K; Veeger Nic J G M; van Gilst Wiek H; van Veldhuisen Dirk J
Compliance in heart failure patients: the importance of knowledge and beliefs.
European heart journal 2006;27(4):434-40.
2006: van de Wal R M A; Plokker H W M; Lok D J A; Boomsma F; van der Horst F A L; van Veldhuisen D J; van Gilst W H; Voors A A
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
International journal of cardiology 2006;106(3):367-72.
2006: Sturm Heidrun B; Haaijer-Ruskamp Flora M; Veeger Nic J; Baljé-Volkers Corine P; Swedberg Karl; van Gilst Wiek H
The relevance of comorbidities for heart failure treatment in primary care: A European survey.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2006;8(1):31-7.
2006: Asselbergs Folkert W; Moore Jason H; van den Berg Maarten P; Rimm Eric B; de Boer Rudolf A; Dullaart Robin P; Navis Gerjan; van Gilst Wiek H
A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study.
BMC medical genetics 2006;7():39.
2005: Voors Adriaan A; van Geel Peter Paul; Buikema Hendrik; Oosterga Margreeth; van Veldhuisen Dirk J; van Gilst Wiek H
High angiotensin II responsiveness is associated with decreased endothelium-dependent relaxation in human arteries.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2005;6(3):145-50.
2005: Westendorp Bart; Schoemaker Regien G; Buikema Hendrik; de Zeeuw Dick; Boomsma Frans; van Gilst Wiek H; van Veldhuisen Dirk J
Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2005;7(7):1085-94.
2005: Westendorp Bart; Schoemaker Regien G; van Gilst Wiek H; van Veldhuisen Dirk J; Buikema Hendrik
Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
European journal of pharmacology 2005;527(1-3):141-9.
2005: Westendorp Bart; Schoemaker Regien G; van Gilst Wiek H; Buikema Hendrik
Improvement of EDHF by chronic ACE inhibition declines rapidly after withdrawal in rats with myocardial infarction.
Journal of cardiovascular pharmacology 2005;46(6):766-72.
2005: Asselbergs Folkert W; van Gilst Wiek H
Urinary albumin excretion and carotid intima-media thickness.
Hypertension 2005;46(6):e20.
2005: White Harvey D; Aylward Philip E G; Huang Zhen; Dalby Anthony J; Weaver W Douglas; Barvik Ståle; Marin-Neto José Antonio; Murin Jan; Nordlander Rolf O; van Gilst Wiek H; Zannad Faiez; McMurray John J V; Califf Robert M; Pfeffer Marc A;
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Circulation 2005;112(22):3391-9.
2005: van der Harst Pim; Wagenaar Lodewijk J; Buikema Hendrik; Voors Adriaan A; Plokker H W Thijs; Morshuis Wim J; Six A Jacob; Boonstra Piet W; Nickenig Georg; Wassmann Sven; van Veldhuisen Dirk J; van Gilst Wiek H
Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
The American journal of cardiology 2005;96(10):1361-4.
2005: van de Wal Ruud M A; van Veldhuisen Dirk J; van Gilst Wiek H; Voors Adriaan A
Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
European heart journal 2005;26(22):2361-7.
2005: van de Wal Ruud M A; Asselbergs Folkert W; Plokker H W Thijs; Smilde Tom D J; Lok Dirk; van Veldhuisen Dirk J; van Gilst Wiek H; Voors Adriaan A
High prevalence of microalbuminuria in chronic heart failure patients.
Journal of cardiac failure 2005;11(8):602-6.
2005: Hernandez Adrian F; Velazquez Eric J; Solomon Scott D; Kilaru Rakhi; Diaz Rafael; O'Connor Christopher M; Ertl George; Maggioni Aldo P; Rouleau Jean-Lucien; van Gilst Wiek; Pfeffer Marc A; Califf Robert M;
Left ventricular assessment in myocardial infarction: the VALIANT registry.
Archives of internal medicine 2005;165(18):2162-9.
2005: van der Meer Peter; Lipsic Erik; Westenbrink B Daan; van de Wal Ruud M A; Schoemaker Regien G; Vellenga Edo; van Veldhuisen Dirk J; Voors Adriaan A; van Gilst Wiek H
Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure.
Circulation 2005;112(12):1743-7.
2005: Asselbergs Folkert W; Piers Lieuwe H; Jessurun Gillian A J; van Boven Ad J; Veeger Nic J G M; Zijlstra Felix; van Gilst Wiek H; Tio René A
Determination of vessel size: a putative framework to assess clinical outcome.
International journal of cardiology 2005;103(2):135-9.
2005: Wagenaar L J; Rahel B M; van Boven A J; Voors A A; van der Wal A C; Plokker H W M; van Gilst W H
Pre-procedural ACE-activity does not predict symptomatic in-stent restenosis.
International journal of cardiology 2005;103(1):73-7.
2005: van der Meer Peter; Lipsic Erik; Henning Robert H; Boddeus Kristien; van der Velden Jolanda; Voors Adriaan A; van Veldhuisen Dirk J; van Gilst Wiek H; Schoemaker Regien G
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
Journal of the American College of Cardiology 2005;46(1):125-33.
2005: Geluk Christiane A; Asselbergs Folkert W; Hillege Hans L; Bakker Stephan J L; de Jong Paul E; Zijlstra Felix; van Gilst Wiek H
Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial.
European heart journal 2005;26(13):1314-20.
2005: van der Harst Pim; Voors Adriaan A; van Gilst Wiek H; van Veldhuisen Dirk J
Statins and autonomic function in chronic heart failure.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2005;19(3):167-8.
2005: Langeveld Bas; Van Gilst Wiek H; Zijlstra Felix
A simple, inexpensive, rapid, and accurate preclinical model for in-stent restenosis.
Journal of the American College of Cardiology 2005;45(8):1310; author reply 1310-1.
2005: Lipsic Erik; van der Horst Iwan C C; Voors Adriaan A; van der Meer Peter; Nijsten Maarten W N; van Gilst Wiek H; van Veldhuisen Dirk J; Zijlstra Felix
Hemoglobin levels and 30-day mortality in patients after myocardial infarction.
International journal of cardiology 2005;100(2):289-92.
2005: Voors Adriaan A; de Kam Pieter J; van den Berg Maarten P; Borghi Claudio; Hochman Judith S; van Veldhuisen Dirk J; van Gilst Wiek H
Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2005;19(2):119-24.
2005: Smilde Tom D J; Asselbergs Folkert W; Hillege Hans L; Voors Adriaan A; Kors Jan A; Gansevoort Ron T; van Gilst Wiek H; de Jong Paul E; Van Veldhuisen Dirk J
Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy.
American journal of hypertension 2005;18(3):342-7.
2005: Asselbergs Folkert W; van Roon Arie M; Hillege Hans L; de Jong Paul E; Gans Reinold O B; Smit Andries J; van Gilst Wiek H;
Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria.
Stroke; a journal of cerebral circulation 2005;36(3):649-53.
2005: Asselbergs Folkert W; van der Harst Pim; Jessurun Gillian A J; Tio René A; van Gilst Wiek H
Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins.
Vascular pharmacology 2005;42(3):125-40.
2005: van de Wal Ruud M A; van Brussel Ben L; Voors Adriaan A; Smilde Tom D J; Kelder Johannes C; van Swieten Henry A; van Gilst Wiek H; van Veldhuisen Dirk Jan; Plokker H W Thijs
Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery.
The Journal of thoracic and cardiovascular surgery 2005;129(2):330-5.
2005: van der Meer Peter; Lipsic Erik; van Gilst Wiek H; van Veldhuisen Dirk J
Erythropoietin: from hematopoiesis to cardioprotection.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2005;19(1):7-8.
2005: Asselbergs Folkert W; van den Berg Maarten P; Diercks Gilles F H; van Gilst Wiek H; van Veldhuisen Dirk J
C-reactive protein and microalbuminuria are associated with atrial fibrillation.
International journal of cardiology 2005;98(1):73-7.
2005: Langeveld Bas; Roks Anton J M; Tio Rene A; Voors Adriaan A; Zijlstra Felix; van Gilst Wiek H
Renin-angiotensin system intervention to prevent in-stent restenosis: an unclosed chapter.
Journal of cardiovascular pharmacology 2005;45(1):88-98.
2005: Langeveld Bas; van Gilst Wiek H; Tio René A; Zijlstra Felix; Roks Anton J M
Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat.
Hypertension 2005;45(1):138-41.
2005: Sturm Heidrun B; van Gilst Wiek H; Swedberg Karl; Hobbs F D Richard; Haaijer-Ruskamp Flora M
Heart failure guidelines and prescribing in primary care across Europe.
BMC health services research 2005;5():57.
2004: de Kam Pieter J; Voors Adriaan A; Fici Francesco; van Veldhuisen Dirk J; van Gilst Wiek H
The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2004;5(4):161-8.
2004: Roks Anton J M; Nijholt Jeroen; van Buiten Azuwerus; van Gilst Wiek H; de Zeeuw Dick; Henning Robert H
Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II.
Journal of hypertension 2004;22(12):2355-61.
2004: van der Meer Peter; Lipsic Erik; Henning Robert H; de Boer Rudolf A; Suurmeijer Albert J H; van Veldhuisen Dirk J; van Gilst Wiek H
Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2004;6(7):853-9.
2004: van der Harst Pim; Volbeda Meint; Voors Adriaan A; Buikema Hendrik; Wassmann Sven; Böhm Michael; Nickenig Georg; van Gilst Wiek H
Vascular response to angiotensin II predicts long-term prognosis in patients undergoing coronary artery bypass grafting.
Hypertension 2004;44(6):930-4.
2004: van de Wal R M A; Voors A A; Plokker H W M; van Gilst W H; van Veldhuisen D J
New pharmacological strategies in chronic heart failure.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2004;18(6):491-501.
2004: van Melle Joost P; Buikema Hendrik; van den Berg Maarten P; van Buiten Azuwerus; van Veldhuisen Dirk J; Boonstra Piet W; van Gilst Wiek H
Sertraline causes strong coronary vasodilation: possible relevance for cardioprotection by selective serotonin reuptake inhibitors.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2004;18(6):441-7.
2004: Velazquez Eric J; Francis Gary S; Armstrong Paul W; Aylward Phillip E; Diaz Rafael; O'Connor Christopher M; White Harvey D; Henis Marc; Rittenhouse Lois M; Kilaru Rakhi; van Gilst Wiek; Ertl Georg; Maggioni Aldo P; Spac Jiri; Weaver W Douglas; Rouleau Jean-Lucien; McMurray John J V; Pfeffer Marc A; Califf Robert M;
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.
European heart journal 2004;25(21):1911-9.
2004: Asselbergs Folkert W; Diercks Gilles F H; Hillege Hans L; van Boven Ad J; Janssen Wilbert M T; Voors Adriaan A; de Zeeuw Dick; de Jong Paul E; van Veldhuisen Dirk J; van Gilst Wiek H;
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Circulation 2004;110(18):2809-16.
2004: Asselbergs Folkert W; Hillege Hans L; van Gilst Wiek H
Framingham score and microalbuminuria: combined future targets for primary prevention?
Kidney international. Supplement 2004;(92):S111-4.
2004: Asselbergs Folkert W; Monnink Stefan H J; Jessurun Gillian A J; van Boven Ad J; Veeger Nic J G M; Zijlstra Felix; van Gilst Wiek H; Tio René A
Assessing the prognostic value of coronary endothelial function in patients referred for a first coronary angiogram.
The American journal of cardiology 2004;94(8):1063-7.
2004: Lipsic Erik; van der Meer Peter; Henning Robert H; Suurmeijer Albert J H; Boddeus Kristien M; van Veldhuisen Dirk J; van Gilst Wiek H; Schoemaker Regien G
Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion.
Journal of cardiovascular pharmacology 2004;44(4):473-9.
2004: de Boer Rudolf A; Pokharel Saraswati; Flesch Markus; van Kampen Derk A; Suurmeijer Albert J H; Boomsma Frans; van Gilst Wiek H; van Veldhuisen Dirk J; Pinto Yigal M
Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.
Journal of molecular medicine (Berlin, Germany) 2004;82(10):678-87.
2004: Voors Adriaan A; van Geel Peter P; Oosterga Margreeth; Buikema Hendrik; van Veldhuisen Dirk J; van Gilst Wiek H
Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2004;5(3):130-4.
2004: Langeveld Bas; Roks Anton J M; Tio René A; van Boven Ad J; van der Want Johannes J L; Henning Rob H; van Beusekom Heleen M M; van der Giessen Willem J; Zijlstra Felix; van Gilst Wiek H
Rat abdominal aorta stenting: a new and reliable small animal model for in-stent restenosis.
Journal of vascular research 2004;41(5):377-86.
2004: Monnink S H J; Tio R A; van Boven A J; van Gilst W H; van Veldhuisen D J
The role of coronary endothelial function testing in patients suspected for angina pectoris.
International journal of cardiology 2004;96(2):123-9.
2004: Loot Annemarieke E; Henning Robert H; Deelman Leo E; Tio René A; Schoen Pieter; Wilschut Jan C; van Gilst Wiek H; Roks Anton J M
Semliki Forest virus is an efficient and selective vector for gene delivery in infarcted rat heart.
Journal of molecular and cellular cardiology 2004;37(1):137-42.
2004: van der Harst Pim; van Gilst Wiek H; Zijlstra Felix
Aggressive lipid-lowering therapy and regression of coronary atheroma.
JAMA : the journal of the American Medical Association 2004;292(1):39; author reply 39-40.
2004: van der Meer Peter; Voors Adriaan A; Lipsic Erik; Smilde Tom D J; van Gilst Wiek H; van Veldhuisen Dirk J
Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.
Journal of the American College of Cardiology 2004;44(1):63-7.
2004: Westendorp Bart; Schoemaker Regien G; Buikema Hendrik; de Zeeuw Dick; van Veldhuisen Dirk J; van Gilst Wiek H
Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2004;5(1):27-32.
2004: van der Meer Peter; Voors Adriaan A; Lipsic Erik; van Gilst Wiek H; van Veldhuisen Dirk J
Erythropoietin in cardiovascular diseases.
European heart journal 2004;25(4):285-91.
2004: Asselbergs F W; de Boer R A; Diercks G F H; Langeveld B; Tio R A; de Jong P E; van Veldhuisen D J; van Gilst W H
Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria?
International journal of cardiology 2004;93(2-3):211-5.
2004: Asselbergs Folkert W; Monnink Stefan H J; Veeger Nic J G M; van Boven Ad J; van Haelst Paul L; Jessurun Gillian A J; van Gilst Wiek H; Tio René A
Coronary vasomotor response is related to the angiographic extent of coronary sclerosis in patients with stable angina pectoris.
Clinical science (London, England : 1979) 2004;106(2):115-20.
2003: de Borst Martin H; Navis Gerjan; de Boer Rudolf A; Huitema Sippie; Vis Lotte M; van Gilst Wiek H; van Goor Harry
Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats.
Laboratory investigation; a journal of technical methods and pathology 2003;83(12):1761-70.
2003: Wagenaar Lodewijk J; van Boven Ad J; van der Wal Allard C; Amoroso Giovanni; Tio René A; van der Loos Chris M; Becker Anton E; van Gilst Wiek H
Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries.
Cardiovascular research 2003;59(4):980-7.
2003: van Haelst P L; Tervaert J W Cohen; van Geel P P; Veeger N J G M; Gurné O; Gans R O B; van Gilst W H
Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2003;26(4):387-91.
2003: van der Meer Peter; van Gilst Wiek H; van Veldhuisen Dirk J
Anemia and congestive heart failure.
Circulation 2003;108(6):e41-2; author reply e41-2.
2003: Gschwend S; Henning R H; Pinto Y M; de Zeeuw D; van Gilst W H; Buikema H
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade.
British journal of pharmacology 2003;139(7):1317-25.
2003: Monnink Stefan H J; Tio René A; Veeger Nic J G M; Amoroso Giovanni; van Boven Ad J; van Gilst Wiek H
Exercise-induced ischemia after successful percutaneous coronary intervention is related to distal coronary endothelial dysfunction.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2003;51(4):221-6.
2003: Pont Lisa G; Sturkenboom Miriam C; van Gilst Wiek H; Denig Petra; Haaijer-Ruskamp Flora M
Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000.
Pharmacoepidemiology and drug safety 2003;12(4):327-34.
2003: Asselbergs Folkert W; van Boven Ad J; Stuveling Erik M; Diercks Gilles F H; Hillege Hans L; Kors Jan A; de Jong Paul E; van Gilst Wiek H;
Relation of electrocardiographic abnormalities to levels of serum C-reactive protein.
The American journal of cardiology 2003;91(11):1358-60.
2003: van Geel Peter Paul; Buikema Hendrik; Rouleau Jean-Lucien; van Gilst Wiek H
Genotype-dependent increase in plasma ACE activity after CABG is prevented by ACE inhibition.
The Canadian journal of cardiology 2003;19(6):701-4.
2003: Mulder H J G H; van Geel P P; Schalij M J; van Gilst W H; Zwinderman A H; Bruschke A V G;
DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial.
Heart (British Cardiac Society) 2003;89(5):557-8.
2003: Pont Lisa G; van Gilst Wiek H; Lok Dirk J A; Kragten Hans J A; Haaijer-Ruskamp Flora M;
The relevance of heart failure severity for treatment with evidence-based pharmacotherapy in general practice.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2003;5(2):187-93.
2003: Gschwend Simone; Buikema Hendrik; Henning Robert H; Pinto Yigal M; de Zeeuw Dick; van Gilst Wiek H
Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2003;5(2):147-54.
2003: Hillege H L; van Gilst W H; van Veldhuisen D J; Navis G; Grobbee D E; de Graeff P A; de Zeeuw D;
Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial.
European heart journal 2003;24(5):412-20.
2003: de Boer Rudolf A; Pinto Yigal M; Suurmeijer Albert J H; Pokharel Saraswati; Scholtens Egbert; Humler Michael; Saavedra Juan M; Boomsma Frans; van Gilst Wiek H; van Veldhuisen Dirk J
Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction.
Cardiovascular research 2003;57(2):434-42.
2003: Voors Adriaan A; Oosterga Margreeth; Buikema Hendrik; Mariani Massimo; Grandjean Jan G; van Gilst Wiek H
Differences between angiotensin-converting enzyme inhibition and angiotensin II-AT1 antagonism on angiotensin-mediated responses in human internal mammary arteries.
Journal of cardiovascular pharmacology 2003;41(2):178-84.
2003: van Veldhuisen Dirk J; van Gilst Wiek H
The pharmacological management of heart failure: too many treatments?
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2003;5(1):5-8.
2002: Wagenaar Lodewijk J; Voors Adriaan A; Buikema Hendrik; van Gilst Wiek H
Angiotensin receptors in the cardiovascular system.
The Canadian journal of cardiology 2002;18(12):1331-9.
2002: Diercks Gilles F H; Hillege Hans L; van Boven Ad J; Kors Jan A; Crijns Harry J G M; Grobbee Diederick E; de Jong Paul E; van Gilst Wiek H
Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes.
Journal of the American College of Cardiology 2002;40(8):1401.
2002: Hillege Hans L; Fidler Vaclav; Diercks Gilles F H; van Gilst Wiek H; de Zeeuw Dick; van Veldhuisen Dirk J; Gans Rijk O B; Janssen Wilbert M T; Grobbee Diederick E; de Jong Paul E;
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.
Circulation 2002;106(14):1777-82.
2002: De Boer R A; Henning R H; Tio R A; Pinto Y M; Brouwer R M H J; Ploeg R J; Böhm M; Van Gilst W H; Van Veldhuisen D J
Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy.
Heart (British Cardiac Society) 2002;88(4):412-4.
2002: Pokharel Saraswati; Rasoul Saman; Roks Anton J M; van Leeuwen Rick E W; van Luyn Marja J A; Deelman Leo E; Smits Jos F; Carretero Oscar; van Gilst Wiek H; Pinto Yigal M
N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts.
Hypertension 2002;40(2):155-61.
2002: Wagenaar Lodewijk J; Voors Adriaan A; Buikema Hendrik; van Buiten Azuwerus; Lübeck Rob H; Boonstra Piet W; van Veldhuisen Dirk J; van Gilst Wiek H
Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2002;16(4):311-6.
2002: Gschwend Simone; Pinto-Sietsma Sara-Joan; Buikema Hendrik; Pinto Yigal M; van Gilst Wiek H; Schulz Angela; de Zeeuw Dick; Kreutz Reinhold
Impaired coronary endothelial function in a rat model of spontaneous albuminuria.
Kidney international 2002;62(1):181-91.
2002: Diercks Gilles F H; Stroes Erik S G; van Boven Ad J; van Roon Arie M; Hillege Hans L; de Jong P E; Smit Andries J; Gans Rijk O B; Crijns Harry J G M; Rabelink Ton J; van Gilst Wiek H
Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects.
Atherosclerosis 2002;163(1):121-6.
2002: de Kam Pieter-Jan; Voors Adriaan A; Brouwer Jan; St John Sutton Martin; van Gilst Wiek H
Approaches to statistical analysis of repeated echocardiographic measurements after myocardial infarction and its relation to heart failure: Application of a random-effects model.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2002;4(3):277-82.
2002: Brundel Bianca J J M; Ausma Jannie; van Gelder Isabelle C; Van der Want Johan J L; van Gilst Wiek H; Crijns Harry J G M; Henning Robert H
Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation.
Cardiovascular research 2002;54(2):380-9.
2002: Diercks G F H; van Boven A J; Hillege J L; de Jong P E; Rouleau J L; van Gilst W H
The importance of microalbuminuria as a cardiovascular risk indicator: A review.
The Canadian journal of cardiology 2002;18(5):525-35.
2002: Roks A J M; Henning R H; van Boven A J; Tio R A; van Gilst W H
Rat abdominal aortic stenting: a simple model displaying in-stent restenosis.
The American journal of cardiology 2002;89(9):1149-50.
2002: Diercks Gilles F H; Stroes Erik S G; Van Boven Ad J; Van Roon Arie M; Hillege Hans L; De Jong Paul E; Smit Andries J; Gans Rijk O B; Crijns Harry J G M; Rabelink Ton J; Van Gilst Wiek H
Difference in the relation between urinary albumin excretion and carotid intima-media thickness in nondiabetic and type 2 diabetic subjects.
Diabetes care 2002;25(5):936-7.
2002: Loot Annemarieke E; Roks Anton J M; Henning Robert H; Tio René A; Suurmeijer Albert J H; Boomsma Frans; van Gilst Wiek H
Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats.
Circulation 2002;105(13):1548-50.
2002: de Kam P J; Nicolosi G L; Voors A A; van den Berg M P; Brouwer J; van Veldhuisen D J; Barlera S; Maggioni A P; Giannuzzi P; Temporelli P L; Latini R; van Gilst W H
Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data.
European heart journal 2002;23(7):536-42.
2002: de Boer Rudolf A; van Geel Peter P; Pinto Yigal M; Suurmeijer Albert J H; Crijns Harry J G M; van Gilst Wiek H; van Veldhuisen Dirk J
Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression.
Journal of cardiovascular pharmacology 2002;39(4):610-9.
2002: Dzau Victor J; Bernstein Kenneth; Celermajer David; Cohen Jerome; Dahlöf Björn; Deanfield John; Diez Javier; Drexler Helmut; Ferrari Roberto; Van Gilst Wiek; Hansson Lennart; Hornig Burkhard; Husain Ahsan; Johnston Colin; Lazar Harold; Lonn Eva; Lüscher Thomas; Mancini John; Mimran Albert; Pepine Carl; Rabelink Ton; Remme Willem; Ruilope Luis; Ruzicka Marcel; Schunkert Heribert; Swedberg Karl; Unger Thomas; Vaughan Douglas; Weber Michael
Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2002;16(2):149-60.
2002: Tio R A; Monnink S H J; Amoroso G; Jessurun G A J; Veeger N; Volkers C; Hautvast R; Tan E S; van Gilst W H; van Boven A J
Safety evaluation of routine intracoronary acetylcholine infusion in patients undergoing a first diagnostic coronary angiogram.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2002;50(2):133-9.
2002: Tio Rene A; Grandjean Jan G; Suurmeijer Albert J H; van Gilst Wiek H; van Veldhuisen Dirk J; van Boven Ad J
Thoracoscopic monitoring for pericardial application of local drug or gene therapy.
International journal of cardiology 2002;82(2):117-21.
2002: Roks A J M; Henning R H; Buikema H; Pinto Y M; Kraak M J J; Tio R A; de Zeeuw D; Haisma H J; Wilschut J; van Gilst W H
Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta.
Gene therapy 2002;9(2):95-101.
2002: Monnink Stefan H J; van Haelst Paul L; van Boven Ad J; Stroes Erik S G; Tio René A; Plokker Thijs W M; Smit Andries J; Veeger Nic J G M; Crijns Harry J G M; van Gilst Wiek H
Endothelial dysfunction in patients with coronary artery disease: a comparison of three frequently reported tests.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2002;50(1):19-24.
2002: Hillege Hans; Van Gilst Wiek; de Zeeuw Dick; van Veldhuisen Dirk-Jan
Renal function as a predictor of prognosis in chronic heart failure.
Heart failure monitor 2002;2(3):78-84.
2001: Dzau V J; Bernstein K; Celermajer D; Cohen J; Dahlöf B; Deanfield J; Diez J; Drexler H; Ferrari R; van Gilst W; Hansson L; Hornig B; Husain A; Johnston C; Lazar H; Lonn E; Lüscher T; Mancini J; Mimran A; Pepine C; Rabelink T; Remme W; Ruilope L; Ruzicka M; Schunkert H; Swedberg K; Unger T; Vaughan D; Weber M;
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.
The American journal of cardiology 2001;88(9A):1L-20L.
2001: Hoffmann S; Krause T; van Geel P P; Willenbrock R; Pagel I; Pinto Y M; Buikema H; van Gilst W H; Lindschau C; Paul M; Inagami T; Ganten D; Urata H
Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy.
Journal of molecular medicine (Berlin, Germany) 2001;79(10):601-8.
2001: Diercks G F; Hillege H L; van Boven A J; Kors J A; Janssen W M; Grobbee D E; Crijns H J; van Gilst W H
Relation between albumin in the urine and electrocardiographic markers of myocardial ischemia in patients without diabetes mellitus.
The American journal of cardiology 2001;88(7):771-4.
2001: Brundel B J; Van Gelder I C; Tuinenburg A E; Wietses M; Van Veldhuisen D J; Van Gilst W H; Crijns H J; Henning R H
Endothelin system in human persistent and paroxysmal atrial fibrillation.
Journal of cardiovascular electrophysiology 2001;12(7):737-42.
2001: Hillege H L; Janssen W M; Bak A A; Diercks G F; Grobbee D E; Crijns H J; Van Gilst W H; De Zeeuw D; De Jong P E;
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity.
Journal of internal medicine 2001;249(6):519-26.
2001: van Geel P P; Pinto Y M; Zwinderman A H; Henning R H; van Boven A J; Jukema J W; Bruschke A V; Kastelein J J; van Gilst W H
Increased risk for ischaemic events is related to combined RAS polymorphism.
Heart (British Cardiac Society) 2001;85(4):458-62.
2001: Brundel B J; Van Gelder I C; Henning R H; Tuinenburg A E; Wietses M; Grandjean J G; Wilde A A; Van Gilst W H; Crijns H J
Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels.
Journal of the American College of Cardiology 2001;37(3):926-32.
2001: de Boer R A; Henning R H; Suurmeijer A J; Pinto Y M; Olthof E; Kirkels J H; van Gilst W H; Crijns H J; van Veldhuisen D J
Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease.
International journal of cardiology 2001;78(1):5-12.
2001: Oosterga M; Voors A A; Pinto Y M; Buikema H; Grandjean J G; Kingma J H; Crijns H J; van Gilst W H
Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia.
The American journal of cardiology 2001;87(5):542-6.
2001: van den Heuvel A F; Dunselman P H; Kingma T; Verhorst P; Boomsma F; van Gilst W H; van Veldhuisen D J
Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade.
Journal of the American College of Cardiology 2001;37(2):470-4.
2001: Brundel B J; Van Gelder I C; Henning R H; Tieleman R G; Tuinenburg A E; Wietses M; Grandjean J G; Van Gilst W H; Crijns H J
Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation.
Circulation 2001;103(5):684-90.
2000: de Kam P J; Voors A A; van den Berg M P; van Veldhuisen D J; Brouwer J; Crijns H J; Borghi C; Ambrosioni E; Hochman J S; LeJemtel T H; Kingma J H; Sutton M S; van Gilst W H
Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators.
Journal of the American College of Cardiology 2000;36(7):2047-53.
2000: Diercks G F; van Boven A J; Hillege H L; Janssen W M; Kors J A; de Jong P E; Grobbee D E; Crijns H J; van Gilst W H
Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study.
European heart journal 2000;21(23):1922-7.
2000: Pinto Y M; Bader M; Pesquero J B; Tschöpe C; Scholtens E; van Gilst W H; Buikema H
Increased kallikrein expression protects against cardiac ischemia.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(13):1861-3.
2000: Diercks G F; Janssen W M; van Boven A J; Bak A A; de Jong P E; Crijns H J; van Gilst W H
Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]).
The American journal of cardiology 2000;86(6):635-8.
2000: Buikema H; Monnink S H; Tio R A; Crijns H J; de Zeeuw D; van Gilst W H
Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure.
British journal of pharmacology 2000;130(8):1999-2007.
2000: Teisman A C; Buikema H; van Veldhuisen D J; de Zeeuw D; van Gilst W H
Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries.
Journal of cardiovascular pharmacology 2000;35(4):581-5.
2000: Teisman A C; van Veldhuisen D J; Boomsma F; de Kam P J; Tjeerdsma G; Pinto Y M; de Zeeuw D; van Gilst W H
Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones.
International journal of cardiology 2000;73(1):7-12; discussion 13-4.
2000: van Geel P P; Pinto Y M; Voors A A; Buikema H; Oosterga M; Crijns H J; van Gilst W H
Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries.
Hypertension 2000;35(3):717-21.
2000: Oosterga M; Voors A A; Buikema H; Pinto Y M; Haber H E; Ebels T; Morshuis W J; Kingma J H; Crijns H J; van Gilst W H
Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2000;14(1):55-60.
2000: Anthonio R L; van Veldhuisen D J; Breekland A; Crijns H J; van Gilst W H
Beta-blocker titration failure is independent of severity of heart failure.
The American journal of cardiology 2000;85(4):509-12, A11.
2000: Teisman A C; Westerink B H; van Veldhuisen D J; Scholtens E; de Zeeuw D; van Gilst W H
Direct interaction between the sympathetic and renin-angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats.
Journal of the autonomic nervous system 2000;78(2-3):117-21.
2000: Anthonio R L; Brodde O E; van Veldhuisen D J; Scholtens E; Crijns H J; van Gilst W H
Beta-adrenoceptor density in chronic infarcted myocardium: a subtype specific decrease of beta1-adrenoceptor density.
International journal of cardiology 2000;72(2):137-41.
2000: van den Heuvel A F; van Veldhuisen D J; van der Wall E E; Blanksma P K; Siebelink H M; Vaalburg W M; van Gilst W H; Crijns H J
Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy.
Journal of the American College of Cardiology 2000;35(1):19-28.
1999: Tio R A; Monnink S H; Jessurun G A; Peels J O; van Boven A J; van Gilst W H; Crijns H G
A comparison of the cold pressor test and the diving test or coronary and systemic hemodynamics in patients with and without coronary artery disease.
International journal of cardiology 1999;71(1):7-15.
1999: Pinto Y M; van Geel P P; Alkfaji H; van Veldhuisen D J; van Gilst W H
Dosing of ACE inhibitors in left ventricular dysfunction: does current clinical dosing provide optimal benefit?
Journal of cardiovascular pharmacology 1999;34 Suppl 1():S13-7.
1999: Roks A J; van Geel P P; Pinto Y M; Buikema H; Henning R H; de Zeeuw D; van Gilst W H
Angiotensin-(1-7) is a modulator of the human renin-angiotensin system.
Hypertension 1999;34(2):296-301.
1999: Tuinenburg A E; Brundel B J; Van Gelder I C; Henning R H; Van Den Berg M P; Driessen C; Grandjean J G; Van Gilst W H; Crijns H J
Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation.
Journal of cardiovascular electrophysiology 1999;10(6):827-35.
1999: Brundel B J; van Gelder I C; Henning R H; Tuinenburg A E; Deelman L E; Tieleman R G; Grandjean J G; van Gilst W H; Crijns H J
Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation.
Cardiovascular research 1999;42(2):443-54.
1999: Van Gelder I C; Brundel B J; Henning R H; Tuinenburg A E; Tieleman R G; Deelman L; Grandjean J G; De Kam P J; Van Gilst W H; Crijns H J
Alterations in gene expression of proteins involved in the calcium handling in patients with atrial fibrillation.
Journal of cardiovascular electrophysiology 1999;10(4):552-60.
1999: Anthonio R L; Brouwer J; Lechat P; Haaksma J; van der Ven L; van Veldhuisen D J; Crijns H J; van Gilst W H
Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]).
The American journal of cardiology 1999;83(8):1286-9, A10.
1998: Teisman A C; Pinto Y M; Buikema H; Flesch M; Böhm M; Paul M; van Gilst W H
Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats.
Journal of hypertension 1998;16(12 Pt 1):1759-65.
1998: Hautvast R W; DeJongste M J; Staal M J; van Gilst W H; Lie K I
Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study.
American heart journal 1998;136(6):1114-20.
1998: Voors A A; Pinto Y M; Buikema H; Urata H; Oosterga M; Rooks G; Grandjean J G; Ganten D; van Gilst W H
Dual pathway for angiotensin II formation in human internal mammary arteries.
British journal of pharmacology 1998;125(5):1028-32.
1998: Böhm M; Ettelbrück S; Flesch M; van Gilst W H; Knorr A; Maack C; Pinto Y M; Paul M; Teisman A C; Zolk O
Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy.
Cardiovascular research 1998;40(1):146-55.
1998: Göbel E J; van Gilst W H; de Kam P J; ter Napel M G; Molhoek G P; Lie K I
Long-term follow-up after early intervention with intravenous diltiazem or intravenous nitroglycerin for unstable angina pectoris.
European heart journal 1998;19(8):1208-13.
1998: van Geel P P; Pinto Y M; Buikema H; van Gilst W H
Is the A1166C polymorphism of the angiotensin II type 1 receptor involved in cardiovascular disease?
European heart journal 1998;19 Suppl G():G13-7.
1998: Oosterga M; Anthonio R L; de Kam P J; Kingma J H; Crijns H J; van Gilst W H
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction.
The American journal of cardiology 1998;81(10):1178-81.
1998: Zolk O; Flesch M; Schnabel P; Teisman A C; Pinto Y M; van Gilst W H; Paul M; Böhm M
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
British journal of pharmacology 1998;123(3):405-12.
1998: Anthonio R L; van Veldhuisen D J; van Gilst W H
Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both?
Journal of cardiovascular pharmacology 1998;32 Suppl 1():S1-8.
1998: van Veldhuisen D J; van Gilst W H; Francis G S
Current insights and new treatment options in heart failure.
Journal of cardiovascular pharmacology 1998;32 Suppl 1():v-vi.
1998: Stula M; Pinto Y M; Gschwend S; Teisman A C; van Gilst W H; Böhm M; Dietz R; Paul M
Interaction of the renin-angiotensin system and the endothelin system in cardiac hypertrophy.
Journal of cardiovascular pharmacology 1998;31 Suppl 1():S403-5.
1997: Cremers T I; Teisman A C; van Gilst W H; Westerink B H
Use of microdialysis for monitoring sympathetic and parasympathetic innervation of heart in conscious rats.
The American journal of physiology 1997;273(6 Pt 2):H2850-6.
1997: de Vries R J; Anthonio R; van Veldhuisen D J; Scholtens E; Buikema H; van Gilst W H
Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction.
Journal of cardiovascular pharmacology 1997;30(5):683-9.
1997: Anthonio R L; van Veldhuisen D J; Scholtens E; van Bekkum C; de Boer E; van Gilst W H
Myocardial infarction with aortic banding. A combined rat model of heart failure.
Japanese heart journal 1997;38(5):697-708.
1997: Roks A J; Pinto Y M; Paul M; Pries F; Stula M; Eschenhagen T; Orzechowski H D; Gschwendt S; Wilschut J; van Gilst W H
Vectors based on Semliki Forest virus for rapid and efficient gene transfer into non-endothelial cardiovascular cells: comparison to adenovirus.
Cardiovascular research 1997;35(3):498-504.
1997: Teisman A C; van Veldhuisen D J; Scholtens E; Maselbas W; van Gilst W H
Effects of selective dopaminergic receptor stimulation on ventricular remodeling after experimental myocardial infarction in rats.
Journal of cardiac failure 1997;3(3):199-205.
1997: van den Broek S A; de Graeff P A; van Veldhuisen D J; van Gilst W H; Hillege H; Wesseling H; Lie K I
Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure.
Journal of cardiac failure 1997;3(3):165-71.
1997: van den Heuvel A F; van Gilst W H; van Veldhuisen D J; de Vries R J; Dunselman P H; Kingma J H
Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators.
Journal of the American College of Cardiology 1997;30(2):400-5.
1997: Voors A A; Oosterga M; Buikema H; May J F; Grandjean J G; van Buiten A; van Gilst W H
Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery.
Cardiovascular research 1997;34(3):568-74.
1997: Buikema H; van Veldhuisen D J; Hegeman H; van Gilst W H
Early pharmacologic intervention may prevent the deterioration in endothelial function after experimental myocardial infarction in rats: effects of ibopamine and captopril.
Journal of cardiac failure 1997;3(2):125-32.
1997: Oosterga M; Voors A A; de Kam P J; Schunkert H; Pinto Y M; Kingma J H; van Gilst W H
Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction.
Circulation 1997;95(12):2607-9.
1997: Buikema H; Pinto Y M; van Geel P P; Rooks G; de Langen C D; de Graeff P A; van Gilst W H
Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity.
Journal of cardiovascular pharmacology 1997;29(5):684-91.
1997: Pinto Y M; Buikema H; van Gilst W H; Scholtens E; van Geel P P; de Graeff P A; Wagner J; Paul M
Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats.
Journal of molecular medicine (Berlin, Germany) 1997;75(5):371-7.
1997: Tieleman R G; Gosselink A T; Crijns H J; van Gelder I C; van den Berg M P; de Kam P J; van Gilst W H; Lie K I
Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone.
The American journal of cardiology 1997;79(1):53-7.
1997: Roks A; Buikema H; Pinto Y M; van Gilst W H
The renin-angiotensin system and vascular function. The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I.
Heart and vessels 1997;Suppl 12():119-24.
1996: Buikema H; Pinto Y M; Rooks G; Grandjean J G; Schunkert H; van Gilst W H
The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries.
European heart journal 1996;17(5):787-94.
1996: Wiesfeld A C; Crijns H J; Van den Broek S A; Landsman M L; Hillege H L; van Gilst W H; Lie K I
Angiographic left ventricular wall motion score to predict arrhythmia recurrence in patients with sustained ventricular tachycardia or fibrillation.
Coronary artery disease 1996;7(3):225-30.
1996: de Vries R J; Dunselman P H; Chin Kon Sung U G; van Veldhuisen D J; Corbeij H M; van Gilst W H; Lie K I
Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure.
Heart (British Cardiac Society) 1996;75(2):159-64.
1996: van den Toren E W; van Veldhuisen D J; van Bruggen A; van den Broek S A; van Gilst W H; Lie K I
Acute hemodynamic and long-term clinical effects of isradipine in patients with coronary artery disease and chronic heart failure. A double-blind, placebo-controlled study.
International journal of cardiology 1996;53(1):37-43.
1996: Pinto Y M; Buikema H; van Gilst W H; Lie K I
Activated tissue renin-angiotensin systems add to the progression of heart failure.
Basic research in cardiology 1996;91 Suppl 2():85-90.
1995: Göbel E J; Hautvast R W; van Gilst W H; Spanjaard J N; Hillege H L; DeJongste M J; Molhoek G P; Lie K I
Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris.
Lancet 1995;346(8991-8992):1653-7.
1995: Voors A A; Kingma J H; van Gilst W H
Drug differences between ACE inhibitors in experimental settings and clinical practice.
Journal of cardiovascular risk 1995;2(5):413-22.
1995: van Veldhuisen D J; Brodde O E; van Gilst W H; Schulze C; Hegeman H; Anthonio R L; Scholtens E; de Graeff P A; Wesseling H; Lie K I
Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril.
Cardiovascular research 1995;30(3):386-93.
1995: Pinto Y M; van Gilst W H; Kingma J H; Schunkert H
Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators.
Journal of the American College of Cardiology 1995;25(7):1622-6.
1995: Pinto Y M; Buikema H; van Gilst W H
Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1995;17(3):441-68.
1995: van Boven A J; de Haan H P; Saleh A E; van Gilst W H; May J F; Lie K I
Hypertension and left ventricular hypertrophy in black people.
Journal of human hypertension 1995;9(3):205-6.
1995: van den Broek S A; de Graeff P A; Smit A J; Girbes A R; Journée; van Gilst W H; Hillege H; van Veldhuisen D J; Wesseling H; Lie K I
Effects of spirapril and captopril on regional blood flow in chronic congestive heart failure: a comparison between a short- and a long-acting angiotensin-converting enzyme inhibitor.
Journal of cardiovascular pharmacology 1995;25(1):105-12.
1994: van der Meer J; Hillege H L; van Gilst W H; Brutel de la Rivière A; Dunselman P H; Fidler V; Kootstra G J; Mulder B J; Pfisterer M; Lie K I
A comparison of internal mammary artery and saphenous vein grafts after coronary artery bypass surgery. No difference in 1-year occlusion rates and clinical outcome. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands.
Circulation 1994;90(5):2367-74.
1994: van der Meer J; Brutel de la Rivière A; van Gilst W H; Hillege H L; Pfisterer M; Kootstra G J; Dunselman P H; Mulder B J; Lie K I
Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Prevention of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole and Acenocoumarol/Phenprocoumon Study.
Journal of the American College of Cardiology 1994;24(5):1181-8.
1994: Tobé T J; de Langen C D; Crijns H J; Wiesfeld A C; van Gilst W H; Faber K G; Lie K I; Wesseling H
Late potentials, QTc prolongation, and prediction of arrhythmic events after myocardial infarction.
International journal of cardiology 1994;46(2):121-8.
1994: van Gilst W H; van Veldhuisen D J; Hegeman H; Buikema H; Scholtens E; de Graeff P A; Lie K I
Effect of ibopamine on ventricular remodeling after experimental myocardial infarction: a comparison with captopril.
Journal of cardiovascular pharmacology 1994;24(1):171-4.
1994: Wout van den Toren E; de Vries R J; Portegies M C; Blanksma P K; van Gilst W H; Hillege H J; van Veldhuisen D J; Lie K I
Effect of isradipine and nifedipine on diastolic function in patients with left ventricular dysfunction due to coronary artery disease: a randomized, double-blind, nuclear, stethoscope study.
Journal of cardiovascular pharmacology 1994;23(6):952-8.
1994: van Veldhuisen D J; van Gilst W H; de Smet B J; de Graeff P A; Scholtens E; Buikema H; Girbes A R; Wesseling H; Lie K I
Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1994;8(2):245-50.
1994: van Wijngaarden J; Smit A J; de Graeff P A; van Gilst W H; van der Broek S A; van Veldhuisen D J; Lie K I; Wesseling H
Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
Journal of cardiovascular pharmacology 1994;23(2):240-5.
1993: Buikema H; van Gilst W H; van Veldhuisen D J; de Smet B J; Scholtens E; Lie K I; Wesseling H
Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine.
Cardiovascular research 1993;27(12):2118-24.
1993: Pinto Y M; de Smet B G; van Gilst W H; Scholtens E; Monnink S; de Graeff P A; Wesseling H
Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology.
Cardiovascular research 1993;27(11):1933-8.
1993: Tobé T J; de Langen C D; Crijns H J; Wiesfeld A C; van Gilst W H; Faber K G; Lie K I; Wesseling H
Effects of streptokinase during acute myocardial infarction on the signal-averaged electrocardiogram and on the frequency of late arrhythmias.
The American journal of cardiology 1993;72(9):647-51.
1993: van Dijk R B; Blanksma P K; van Gilst W H; Lie K I
Influence of intravenous diltiazem on left ventricular function in patients with severe coronary artery disease at rest and during pacing, monitored by computer-processed nuclear probe and tip-manometer data.
Journal of cardiovascular pharmacology 1993;22(2):215-20.
1993: van der Meer J; Hillege H L; Kootstra G J; Ascoop C A; Mulder B J; Pfisterer M; van Gilst W H; Lie K I
Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands.
Lancet 1993;342(8866):257-64.
1993: van den Broek S A; van Veldhuisen D J; de Graeff P A; Crijns H J; van Gilst W H; Hillege H; Lie K I
Mode of death in patients with congestive heart failure: comparison between possible candidates for heart transplantation and patients with less advanced disease.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1993;12(3):367-71.
1993: van Veldhuisen D J; Girbes A R; van den Broek S A; de Graeff P A; van Gilst W H; Lie K I
Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure.
The American journal of cardiology 1993;71(11):992-4.
1992: Buikema H; Grandjean J G; van den Broek S; van Gilst W H; Lie K I; Wesseling H
Differences in vasomotor control between human gastroepiploic and left internal mammary artery.
Circulation 1992;86(5 Suppl):II205-9.
1992: Tobé T J; de Langen C D; Mook P H; Tio R A; Bel K J; de Graeff P A; van Gilst W H; Wesseling H
Late potentials in a porcine model of anterior wall myocardial infarction and their relation to inducible ventricular tachycardia.
Pacing and clinical electrophysiology : PACE 1992;15(11 Pt 1):1760-71.
1992: Wiesfeld A C; Crijns H J; Van Veldhuisen D J; Van Gilst W H; Lie K I
Triggered activity as arrhythmogenic mechanism after myocardial infarction: clinical and electrophysiologic study of one case.
Clinical cardiology 1992;15(9):689-92.
1992: van Wijngaarden J; Monnink S H; Bartels H; van Gilst W H; de Graeff P A; de Langen C D; Wesseling H
Captopril modifies the response of infarcted rat hearts to isoprenaline stimulation.
Journal of cardiovascular pharmacology 1992;19(5):741-7.
1992: Tobé T J; de Langen C D; Weersink E G; van Wijngaarden J; Bel K J; de Graeff P A; van Gilst W H; Wesseling H
The angiotensin converting enzyme inhibitor perindopril improves survival after experimental myocardial infarction in pigs.
Journal of cardiovascular pharmacology 1992;19(5):732-40.
1992: van Wijngaarden J; Tobé T J; Weersink E G; Bel K J; de Graeff P A; de Langen C D; van Gilst W H; Wesseling H
Effects of early angiotensin-converting enzyme inhibition in a pig model of myocardial ischemia and reperfusion.
Journal of cardiovascular pharmacology 1992;19(3):408-16.
1992: Tio R A; de Langen C D; Mook P H; Bel K J; Wolters G T; van Gilst W H; de Graeff P A; Wesseling H
Neurohumoral changes and the inducibility of ventricular tachycardias: effect of early reperfusion on the ischemic porcine myocardium.
Archives internationales de pharmacodynamie et de thérapie 1992;316():43-59.
1992: van Gilst W H; Tio R A; van Wijngaarden J; de Graeff P A; Wesseling H
Effects of converting enzyme inhibitors on coronary flow and myocardial ischemia.
Journal of cardiovascular pharmacology 1992;19 Suppl 5():S134-9.
1991: van Wijngaarden J; Pinto Y M; van Gilst W H; de Graeff P A; de Langen C D; Wesseling H
Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril.
Cardiovascular research 1991;25(11):936-42.
1991: van Gilst W H; Kingma J H
Early intervention with angiotensin-converting enzyme inhibitors during thrombolytic therapy in acute myocardial infarction: rationale and design of captopril and thrombolysis study. CATS investigators group.
The American journal of cardiology 1991;68(14):111D-115D.
1991: van den Broek S A; van Bruggen A; de Graeff P A; Hillege H; van Gilst W H; Wesseling H; Lie K I
The acute hemodynamic, hormonal, and pharmacokinetic properties of oral spirapril in patients with moderate to severe heart failure.
Journal of cardiovascular pharmacology 1991;18(4):614-21.
1991: van Gilst W H; de Graeff P A; de Leeuw M J; Scholtens E; Wesseling H
Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators.
Journal of cardiovascular pharmacology 1991;18(3):429-36.
1991: Crijns H J; Van Gelder I C; Van Gilst W H; Hillege H; Gosselink A M; Lie K I
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
The American journal of cardiology 1991;68(4):335-41.
1991: Van Gelder I C; Crijns H J; Van Gilst W H; Verwer R; Lie K I
Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter.
The American journal of cardiology 1991;68(1):41-6.
1991: van Wijngaarden J; Tio R A; van Gilst W H; de Graeff P A; de Langen C D; Wesseling H
Coronary vasodilation induced by captopril and zofenoprilat: evidence for a prostaglandin-independent mechanism.
Naunyn-Schmiedeberg's archives of pharmacology 1991;343(5):491-5.
1991: Tio R A; Tobé T J; Bel K J; de Langen C D; van Gilst W H; Wesseling H
Beneficial effects of bradykinin on porcine ischemic myocardium.
Basic research in cardiology 1991;86(2):107-16.
1991: Van Gelder I C; Crijns H J; Van Gilst W H; Hamer H P; Lie K I
Decrease of right and left atrial sizes after direct-current electrical cardioversion in chronic atrial fibrillation.
The American journal of cardiology 1991;67(1):93-5.
1991: Van Gelder I C; Crijns H J; Van der Laarse A; Van Gilst W H; Lie K I
Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter.
American heart journal 1991;121(1 Pt 1):51-6.
1991: Pinto Y M; van Wijngaarden J; van Gilst W H; de Graeff P A; Wesseling H
The effects of short- and long-term treatment with an ACE-inhibitor in rats with myocardial infarction.
Basic research in cardiology 1991;86 Suppl 1():165-72.
1991: Van Veldhuisen D J; Girbes A R; Crijns H J; Smit A J; Van Gilst W H; Lie K I
The oral dopamine agonist, ibopamine, in normal man: effects on rhythm, heart rate, blood pressure and catecholamines.
International journal of clinical pharmacology research 1991;11(3):159-65.
1990: Tio R A; de Langen C D; de Graeff P A; van Gilst W H; Bel K J; Wolters K G; Mook P H; van Wijngaarden J; Wesseling H
The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1990;4(3):695-703.
1990: van Wijk L M; Crijns H J; Kingma H J; van Gilst W H; van Gelder I C; Wesseling H; Lie K I
Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation.
Journal of cardiovascular pharmacology 1990;15(6):884-91.
1990: van Wijngaarden J; Tio R A; van Gilst W H; de Graeff P A; de Langen C D; Wesseling H
Basic pharmacology of ACE-inhibitors with respect to ischaemic heart disease: prostaglandins and bradykinin.
European heart journal 1990;11 Suppl B():84-93.
1990: van den Berg M P; Viersma J W; van Gilst W H; Lie K I
Xamoterol in autonomic and intrinsic sinus node dysfunction.
The American journal of cardiology 1990;65(11):814-6.
1990: Tio R A; van Gilst W H; Rett K; Wolters K; Dietze G J; Wesseling H
The effects of bradykinin and the ischemic isolated rat heart.
Hormone and metabolic research. Supplement series 1990;22():85-9.
1989: Tio R A; Heiligers J P; de Langen C D; van Gilst W H; König W; Saxena P R; Wesseling H
The haemodynamic effects of two angiotensin converting enzyme inhibitors, enalaprilat and zofenoprilat, in the rat: evidence for the involvement of bradykinin.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1989;7(6):S296-7.
1989: Van Gelder I C; Crijns H J; Van Gilst W H; Van Wijk L M; Hamer H P; Lie K I
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
The American journal of cardiology 1989;64(19):1317-21.
1989: Wesseling H; de Graeff P A; van Gilst W H; Kingma J H; de Langen C D
Cardiac arrhythmias--a new indication for angiotensin-converting enzyme inhibitors?
Journal of human hypertension 1989;3 Suppl 1():89-95.
1989: van Wijk L M; Crijns H J; van Gilst W H; Wesseling H; Lie K I
Flecainide acetate in the treatment of supraventricular tachycardias: value of programmed electrical stimulation for long-term prognosis.
American heart journal 1989;117(2):365-9.
1989: de Langen C D; de Graeff P A; van Gilst W H; Bel K J; Kingma J H; Wesseling H
Effects of angiotensin II and captopril on inducible sustained ventricular tachycardia two weeks after myocardial infarction in the pig.
Journal of cardiovascular pharmacology 1989;13(2):186-91.
1989: Van Gelder I C; Crijns H J; Van Gilst W H; De Langen C D; Van Wijk L M; Lie K I
Effects of flecainide on the atrial defibrillation threshold.
The American journal of cardiology 1989;63(1):112-4.
1989: van Wijk L M; den Heijer P; Crijns H J; van Gilst W H; Lie K I
Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation.
Journal of cardiovascular pharmacology 1989;13(1):32-6.
1989: Tio R A; van Wijngaarden J; Scholtens E; van Gilst W H; de Langen C D; Wesseling H
The increase in coronary flow induced by converting enzyme inhibitors is prostacyclin independent.
Progress in clinical and biological research 1989;301():435-9.
1989: van Gilst W H
Protection of the myocardium against postischemic reperfusion damage.
Journal of cardiovascular pharmacology 1989;14 Suppl 9():S49-54.
1988: van Gilst W H; Tijssen J G; van Es G A; Lubsen J
Serum potassium values in relation to the use of diuretics in patients with unstable angina pectoris.
European heart journal 1988;9(7):795-9.
1988: van Gilst W H; Scholtens E; de Graeff P A; de Langen C D; Wesseling H
Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation.
Circulation 1988;77(6 Pt 2):I24-9.
1988: Crijns H J; van Wijk L M; van Gilst W H; Kingma J H; van Gelder I C; Lie K I
Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens.
European heart journal 1988;9(6):634-8.
1988: van Gelder I C; Crijns H J; van Wijk L M; van Gilst W H; Lie K I
Abnormal pharmacokinetics of flecainide in a "nonresponder".
Clinical cardiology 1988;11(5):353-5.
1988: deGraeff P A; deLangen C D; van Gilst W H; Bel K; Scholtens E; Kingma J H; Wesseling H
Protective effects of captopril against ischemia/reperfusion-induced ventricular arrhythmias in vitro and in vivo.
The American journal of medicine 1988;84(3A):67-74.
1987: van Gilst W H; de Graeff P A; Scholtens E; de Langen C D; Wesseling H
Potentiation of isosorbide dinitrate-induced coronary dilatation by captopril.
Journal of cardiovascular pharmacology 1987;9(2):254-5.
1987: de Graeff P A; van Gilst W H; Bel K; de Langen C D; Kingma J H; Wesseling H
Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed chest pig model.
Journal of cardiovascular pharmacology 1987;9 Suppl 2():S37-42.
1987: van Gilst W H; van Wijngaarden J; Scholtens E; de Graeff P A; de Langen C D; Wesseling H
Captopril-induced increase in coronary flow: an SH-dependent effect on arachidonic acid metabolism?
Journal of cardiovascular pharmacology 1987;9 Suppl 2():S31-6.
1986: Viersma J W; van den Berg M P; van Gilst W H; Lie K I
Intrinsic sympathomimetic activity (ISA) of pindolol in patients with sinus node dysfunction.
European heart journal 1986;7(1):42-6.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Wiek van Gilst

Research Profile (preview)

Chemicals & Drugs

Disorders

Living Beings

Anatomy

Concepts & Ideas

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Wiek van Gilst (preview)

All Publications